{"id":1800,"date":"2017-05-09T16:24:03","date_gmt":"2017-05-09T16:24:03","guid":{"rendered":"https:\/\/sites.austincc.edu\/incubator\/?p=1800"},"modified":"2022-03-29T17:22:12","modified_gmt":"2022-03-29T17:22:12","slug":"new-member-company-curtana-pharmaceuticals","status":"publish","type":"post","link":"https:\/\/sites.austincc.edu\/incubator\/new-member-company-curtana-pharmaceuticals\/","title":{"rendered":"New member company, Curtana Pharmaceuticals"},"content":{"rendered":"

[et_pb_section admin_label=”section”][et_pb_row admin_label=”Row”][et_pb_column type=”2_3″][et_pb_text admin_label=”Text” background_layout=”light” text_orientation=”left” use_border_color=”off” border_color=”#ffffff” border_style=”solid”]<\/p>\n

Curtana Pharmaceuticals<\/a> is developing highly targeted therapies for the treatment of brain cancer, including glioblastoma in adults and pediatric high grade glioma in children.<\/p>\n

Patients typically are treated with surgery, radiation, and chemotherapy. Unfortunately, current treatments offer little hope of significantly prolonging a patient\u2019s life.<\/p>\n

Curtana is advancing a novel small molecule therapy, CT-179, which has been shown to significantly prolong survival in relevant animal models. The target is Olig2, a cancer stem cell-associated transcription factor that is critical for tumor initiation and growth. CT-179 will enter clinical development in early 2018.<\/p>\n

Learn more at:\u00a0www.curtanapharma.com<\/a><\/p>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=”1_3″][et_pb_image admin_label=”Image” src=”https:\/\/sites.austincc.edu\/incubator\/wp-content\/uploads\/sites\/154\/2016\/06\/Curtana500.jpg” alt=”Curtana Pharma Logo” show_in_lightbox=”off” url_new_window=”off” use_overlay=”off” animation=”off” sticky=”off” align=”left” force_fullwidth=”off” always_center_on_mobile=”on” use_border_color=”off” border_color=”#ffffff” border_style=”solid”] [\/et_pb_image][et_pb_social_media_follow admin_label=”Social Media Follow” link_shape=”rounded_rectangle” background_layout=”light” url_new_window=”off” follow_button=”off”] [et_pb_social_media_follow_network social_network=”twitter” url=”https:\/\/twitter.com\/CurtanaPharma” skype_action=”call” bg_color=”#00aced”] Twitter [\/et_pb_social_media_follow_network][et_pb_social_media_follow_network social_network=”linkedin” url=”https:\/\/www.linkedin.com\/company-beta\/3187723″ skype_action=”call” bg_color=”#007bb6″] LinkedIn [\/et_pb_social_media_follow_network] [\/et_pb_social_media_follow][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"

Curtana Pharmaceuticals is developing highly targeted therapies for the treatment of brain cancer, including glioblastoma in adults and pediatric high grade glioma in children. Patients typically are treated with surgery, radiation, and chemotherapy. Unfortunately, current treatments offer little hope of significantly prolonging a patient\u2019s life. Curtana is advancing a novel small molecule therapy, CT-179, which […]<\/p>\n","protected":false},"author":4006,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[1],"tags":[35,51,53,74],"class_list":["post-1800","post","type-post","status-publish","format-standard","hentry","category-press-and-recognition","tag-austin","tag-biotechnology","tag-glioblastoma","tag-member-companies"],"acf":{"featured_banner":""},"_links":{"self":[{"href":"https:\/\/sites.austincc.edu\/incubator\/wp-json\/wp\/v2\/posts\/1800","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/sites.austincc.edu\/incubator\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/sites.austincc.edu\/incubator\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/sites.austincc.edu\/incubator\/wp-json\/wp\/v2\/users\/4006"}],"replies":[{"embeddable":true,"href":"https:\/\/sites.austincc.edu\/incubator\/wp-json\/wp\/v2\/comments?post=1800"}],"version-history":[{"count":0,"href":"https:\/\/sites.austincc.edu\/incubator\/wp-json\/wp\/v2\/posts\/1800\/revisions"}],"wp:attachment":[{"href":"https:\/\/sites.austincc.edu\/incubator\/wp-json\/wp\/v2\/media?parent=1800"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/sites.austincc.edu\/incubator\/wp-json\/wp\/v2\/categories?post=1800"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/sites.austincc.edu\/incubator\/wp-json\/wp\/v2\/tags?post=1800"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}